Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

ConclusionsOur findings show that PK simulations of early clinical data together with ex vivo cytotoxicity estimates can inform the identification of a bispecific antibody ’s therapeutic range.Clinical Trial RegistrationNCT03145181, date of registration: May 9, 2017.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research